ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Aug. 29, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a narrated overview of second quarter 2018 operational results.
"We continued to make significant progress on three main priorities in the second quarter of 2018", stated ProMIS Executive Chairman, Eugene Williams. "First, to maintain PMN310 on track for clinical trial start in the second half of 2019 with initiation of cell line development supporting product manufacturing; second, to differentiate the oligomer selectivity of PMN310 as best in class profile for the treatment of Alzheimer's disease (AD) versus other, less selective amyloid-beta (Ab) directed therapies in development; and third, to expand our portfolio by developing therapeutic antibodies targeting toxic oligomers of alpha-synuclein for Parkinson's disease (PD) and toxic aggregates of Tar-DNA binding protein (TDP43) for ALS, with a view to partnering these assets."
The narrated overview can be found on the ProMIS Neurosciences website by clicking on the link below:
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company's website at:
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content with multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-issues-narrated-overview-of-second-quarter-2018-results-300703933.html
SOURCE ProMIS Neurosciences Inc.
Released August 29, 2018